Advertisement
Advertisement

RCEL

RCEL logo

Avita Medical, Inc. Common Stock

3.99
USD
Sponsored
0.00
0.00%
Mar 26, 12:49 UTC -4
Open

RCEL Earnings Reports

Positive Surprise Ratio

RCEL beat 7 of 16 last estimates.

44%

Next Report

Date of Next Report
May 06, 2026
Estimate for Q1 26 (Revenue/ EPS)
$18.54M
/
-$0.28
Implied change from Q4 25 (Revenue/ EPS)
+5.24%
/
-26.32%
Implied change from Q1 25 (Revenue/ EPS)
+0.13%
/
-47.17%

Avita Medical, Inc. Common Stock earnings per share and revenue

On Jan 13, 2026, RCEL reported earnings of -0.38 USD per share (EPS) for Q4 25, missing the estimate of -0.34 USD, resulting in a -10.88% surprise. Revenue reached 17.62 million, compared to an expected 17.82 million, with a -1.13% difference. The market reacted with a +6.67% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 5 analysts forecast an EPS of -0.28 USD, with revenue projected to reach 18.54 million USD, implying an decrease of -26.32% EPS, and increase of 5.24% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Theravance Biopharma, Inc.
Report Date
Mar 19, 2026 For Q4 25
Estimate
$1.24
Actual
$0.21
Surprise
-83.12%
logo
Context Therapeutics Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$0.10
Actual
-$0.14
Surprise
-29.39%
logo
Avalo Therapeutics, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$1.49
Actual
-$1.12
Surprise
+24.33%
logo
Journey Medical Corporation Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.04
Surprise
+31.86%
logo
Surrozen, Inc. Common
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$1.21
Actual
-
Surprise
-
logo
Achieve Life Sciences, Inc.
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.28
Surprise
-1.12%
logo
Pyxis Oncology, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$0.34
Actual
-$0.28
Surprise
+15.55%
logo
Acrivon Therapeutics, Inc. Common Stock
Report Date
Mar 19, 2026 For Q4 25
Estimate
-$0.47
Actual
-$0.52
Surprise
-9.34%
logo
Fractyl Health, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.18
Actual
$0.15
Surprise
+181.70%
logo
NRX Pharmaceuticals, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
$0.00
Actual
-$0.01
Surprise
-361.54%
FAQ
For Q4 2025, Avita Medical, Inc. Common Stock reported EPS of -$0.38, missing estimates by -10.88%, and revenue of $17.62M, -1.13% below expectations.
The stock price moved up 6.67%, changed from $3.30 before the earnings release to $3.52 the day after.
The next earning report is scheduled for May 06, 2026.
Based on 5 analysts, Avita Medical, Inc. Common Stock is expected to report EPS of -$0.28 and revenue of $18.54M for Q1 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement